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Abstract
Background: Malaria transmission intensity is a crucial determinant of malarial disease burden and its measurement can
help to define health priorities. Rapid, local estimates of transmission are required to focus resources better but current
entomological and parasitological methods for estimating transmission intensity are limited in this respect. An alternative is
determination of antimalarial antibody age-specific sero-prevalence to estimate sero-conversion rates (SCR), which have
been shown to correlate with transmission intensity. This study evaluated SCR generated from samples collected from
health facility attendees as a tool for a rapid assessment of malaria transmission intensity.
Methodology and Principal Findings: The study was conducted in north east Tanzania. Antibodies to Plasmodium
falciparum merozoite antigens MSP-119 and AMA-1 were measured by indirect ELISA. Age-specific antibody prevalence was
analysed using a catalytic conversion model based on maximum likelihood to generate SCR. A pilot study, conducted near
Moshi, found SCRs for AMA-1 were highly comparable between samples collected from individuals in a conventional cross-
sectional survey and those collected from attendees at a local health facility. For the main study, 3885 individuals attending
village health facilities in Korogwe and Same districts were recruited. Both malaria parasite prevalence and sero-positivity
were higher in Korogwe than in Same. MSP-119 and AMA-1 SCR rates for Korogwe villages ranged from 0.03 to 0.06 and 0.07
to 0.21 respectively. In Same district there was evidence of a recent reduction in transmission, with SCR among those born
since 1998 [MSP-119 0.002 to 0.008 and AMA-1 0.005 to 0.014 ] being 5 to 10 fold lower than among individuals born prior to
1998 [MSP-119 0.02 to 0.04 and AMA-1 0.04 to 0.13]. Current health facility specific estimates of SCR showed good
correlations with malaria incidence rates in infants in a contemporaneous clinical trial (MSP-119 r
2=0.78, p,0.01 & AMA-1
r
2=0.91, p,0.001).
Conclusions: SCRs generated from age-specific anti-malarial antibody prevalence data collected via health facility surveys
were robust and credible. Analysis of SCR allowed detection of a recent drop in malaria transmission in line with recent data
from other areas in the region. This health facility-based approach represents a potential tool for rapid assessment of recent
trends in malaria transmission intensity, generating valuable data for local and national malaria control programs to target,
monitor and evaluate their control strategies.
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Introduction
Recent years have seen the widespread implementation of
various malaria control strategies including the use of insecticide
impregnated mosquito nets (ITN), insecticide residual spraying
(IRS) and artemisinin combination therapies (ACT) [1–3].
Moreover, there is evidence that malaria transmission is
decreasing in several areas in sub-Saharan Africa [4–8]. These
successes, together with a considerable increase in funds available
for malaria control activities, have sparked renewed optimism for
malaria elimination programmes [9,10]. A key element in focusing
control and elimination efforts will be obtaining reliable measures
of malaria transmission intensity (MTI) which is a crucial
determinant of the burden of malaria disease [11–13]. However,
it is not clear how best to monitor changes in transmission and
disease burden [14]. Moreover, transmission of malaria is notably
heterogeneous and different control measures may be better suited
to different transmission intensities. Similarly, different methods
(and combinations of methods) with differing provenance and
characteristics will be needed for measuring transmission at
different levels [12]. As such, a technique that generates locally
applicable measures of MTI and in a rapid, logistically feasible
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6083manner would have great potential for use by district and national
malaria control teams.
The current gold-standard for measuring MTI is the Entomo-
logical Inoculation Rate (EIR), determined as the number of
infectious bites per person per year (ib/p/yr). EIRs vary across
Africa, ranging from less than one to greater than 1000 ib/p/yr
[15]. Despite its undoubted relevance and provision of important
information on mosquito species and temporal dynamics, determi-
nation of EIR is not suited to obtaining rapid estimates of MTI. It is
typically a laborious and time-consuming method; moreover
mosquito distributions are notably heterogeneous [16–18] with
intensive sampling required to provide robust estimates at fine scale
and at low mosquito densities. Parasite prevalence (PR), estimated
by microscopy or, increasingly, by Rapid Diagnostic Tests (RDTs),
has similar limitations. Whilst PR can be estimated reasonably
quickly, the resulting prevalence is limited by the sensitivity of the
assay used and estimates can be profoundly influenced by anti-
malarial drug intake and the timing of collection, especially in areas
of seasonal transmission; PR also has limited sensitivity to measure
changes at the high and low ends of the spectrum of transmission
intensities [19]. Estimation of PR using molecular techniques has
increased sensitivity but is time consuming and requires skills and
equipment unlikely to be available in many resource-poor settings.
An alternative measure of MTI is the prevalence of anti-malarial
antibodies in the local population. Previously, a sero-epidemiological
approach to evaluate exposure to malaria was widely advocated but
its uptake was limited by the requirement for cultured parasites as a
source of antigen and a lack of objective criteria for determining
sero-positivity [20–22]. More recently, objective analysis of ELISA
data (obtained using recombinant malaria antigens) has shown
considerable promise, with antibody sero-conversion rates (SCR)
showing tight correlation with EIR [23]. The advantages of this
approach are several. Antibody responses represent an integration of
malaria exposure over time and allow an evaluation of temporal
trends in transmission. The longevity of the antibody response
generates sero-prevalences that are higher than equivalent parasite
rates and the method thus has greater sensitivity in low transmission
settings. Technically, SCR assays are simple, cheap and quick to
perform and can be adapted to different transmission settings by
using antigens of differing immunogenicity [24]. One operational
benefit is that antibodies can be eluted from filter paper thereby
simplifying sample collection and storage in field conditions [25].
Inthis studywehaveexaminedthe utilityofserological markers of
malaria exposure to rapidly assess MTI in an area of northeast
Tanzania. A pilot study was conducted to compare sero-prevalence
data from samples collected in cross-sectional surveys with samples
from attendees at the health facility in the same community. The
latter approach relies on sampling all individuals attending a health
facility over a fixed period of time (or until the required number of
samples have been obtained), including malaria and non-malaria
casesand healthycompanions.Sero-prevalencedata collectedacross
all age groups, within the context of a large scale intermittent
presumptive treatment trial in infants (the KILI-IPTi study) [26],
were converted into SCR and used to estimate current and recent
trends in malaria transmission. The study demonstrated the utility of
rapid assessment ofSCR forobtaining realisticestimatesofMTI and
provided important contextual information to aid interpretation of
the results from the IPTi study.
Methods
Study Site
The study was conducted in north east Tanzania where malaria
transmission is associated with the two annual rainy seasons; there
is marked small scale heterogeneity in malaria transmission
associated with altitude and rainfall [27].
Pilot study
Samples were collected from subjects recruited at the Msitu wa
Tembo health facility in lower Moshi (Figure 1) in a 3 week period
in February 2007. This is a low malaria transmission area on the
slopes of mount Kilimanjaro with an EIR of ,3 ib/p/yr [28]
where we have previously conducted a cross-sectional malaria
prevalence surveys. Eligible participants were any attendee at the
health facility for any reason (i.e. family members or guardians
accompanying patients as well as patients themselves) who
consented to take part. There were no age or gender restrictions.
Study details were explained to all potential adult and guardians of
child participants. Subsequently, signed or fingerprinted informed
consent was obtained for adults and guardians of child participants
prior to enrolment. A copy of the consent form was offered to all
subjects. Staff at the health facility were informed of the study
during a group sensitization session at both the Outpatient
Department (OPD) and Maternal and Child Health (MCH)
sections of the clinic. Study information sheets in Kiswahili were
posted at the clinic.
Consenting participants were registered and assigned a unique
ID number which corresponded to the district, dispensary and
patient number. Additional information on age, sex and village of
residence was collected. Blood samples were collected from finger
pricks into an EDTA-coated micro-tube, onto filter paper (3MM
Whatman) and onto a rapid diagnostic test (RDT; Parahit-f, Span
Diagnostics Limited). RDT results were given to the prescribing
officer to assist in patient management. Filter papers stored, after
rigorous air drying, in a sealed container containing silica gel as a
desiccant, as described previously [25] and were returned, with the
EDTA blood sample, to the laboratory at Kilimanjaro Christian
Medical Centre (KCMC) for same-day processing, storage and
subsequent analysis.
Plasma samples were also obtained from a cross-sectional survey
carried out in the village of Msitu wa Tembo in 2005 (for survey
methodology see [29]).
IPTi study
Subjects were recruited from health facilities within the
Korogwe and Same Districts of Tanzania between July and
August 2007. Korogwe district is a moderate transmission site
located in the Tanga region and Same district is categorized as a
low transmission site located to the north and further inland than
Korogwe [27] (Figure 1). Four health facilities per district
(Korogwe: Magunga, Majengo, Mnyuzi and Magasin; and Same:
Same District Hospital, Kisiwani, Gonja Moare and Ndungu
Health Centre) were selected based on their involvement within
the Kili-IPTi study [26] (Figure 1).
Consenting participants were enrolled as for the pilot study and
finger prick blood samples collected onto filter paper and RDTs.
Filter paper samples were collected, dried, stored at 4uC in air
tight containers with desiccant and transported to the KCMC
biotechnology laboratory after ,2 weeks.
Samples for ELISA assays
I. Plasma. EDTA blood samples were centrifuged for
5 minutes (13,000 rpm) and the plasma removed and stored at
220uC. Prior to analysis plasma samples were diluted 1:1000 with
PBS containing 0.1%Tween 20 (Sigma, US).
II. Reconstitution of Filter PaperBlood Spots. Briefly, using
a hole punch, a 2.5 mm blood spot (equivalent to approximately
1.5 ml of blood) was removed from the filter paper and placed into
Measuring Malaria Transmission
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To each well, 150 ml of reconstitution buffer (PBS plus
0.05%Tween and 0.1% (w/v) sodium azide) was added. Sample
plates were sealed and rocked gently at room temperature
overnight before storage at 4uC until use. The reconstituted
blood spot solution was equivalent to a 1/100 dilution of whole
blood or 1/200 of serum (assuming a haematocrit of approximately
50%). Ultimately, the final serum dilution equivalent on the
processed ELISA plate was 1/1000.
Enzyme-linked immunosorbent assay
All test samples (plasma, reconstituted filter paper spots) were
tested for anti-MSP-119 and anti-AMA-1 human IgG antibodies
by ELISA using standard methodology [23,25]. Briefly, recombi-
nant MSP-119 (Wellcome genotype) and AMA-1 (3D7) were
coated overnight at 4uC at a concentration of 0.5 mg/ml
respectively. Plates were washed using PBS plus 0.05% Tween
20 (PBS/T) and blocked with 1% (w/v) skimmed milk powder in
PBS/T. Samples, a positive (a pool of hyperimmune serum
collected from a malaria endemic area) and negative controls
(serum from European malaria naı ¨ve volunteers) were added in
duplicate to each plate. After washing, horseradish peroxidase-
conjugated rabbit anti-human IgG (DAKO) (1/5000 in PBS/T)
was added to all wells. All plates were developed using OPD
substrate solution and reactions were stopped with 2 M H2SO4.
Plates were read immediately at 492 nm and optical density (OD)
values recorded.
Sample size calculations
Sample sizes were calculated by fitting an empirical function to
the results of previous studies [23] to determine how the % relative
standard deviation (%RSD; equivalent to the coefficient of
variance) scales with the number of positive individuals sampled.
A logarithmic function was fitted and used to calculate a sample
size (N) necessary to generate sufficient sero-positive samples at
different values of SCR to give the required %RSD. It was
assumed that the low transmission site in Moshi and Same had a
SCR of 0.05/yr (EIR,3) and for a 20% RSD 237 samples are
required. The equivalent value for the high transmission sites with
an assumed SCR of 1.0 and 20% RSD was 160 samples.
Figure 1. Map showing the study area: Squares mark major towns, circles mark villages with study dispensaries.
doi:10.1371/journal.pone.0006083.g001
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PLoS ONE | www.plosone.org 4 June 2009 | Volume 4 | Issue 6 | e6083These samples sizes were incorporated into a logistically viable
operational approach which allowed for the varying levels of
attendance at the different health facilities and for the fact that
samples were collected over a similar time period. Ultimately a
study pack containing sufficient data forms, filter papers, RDT’s
and storage boxes for 500 individuals was left at each health
facility. Completed study packs and samples were collected from
dispensaries once a week, during routine supervision visits.
Statistical Methods
For each sample duplicate OD results were averaged and
normalized against the positive control run on each plate.
Figure 2. Age sero-prevalence plots for antibody responses to P. falciparum parasite antigens MSP-119 (fig 2a) and AMA-1 (figure
2b) from the pilot study (Msitu wa Tembo). Open circles (and confidence limits) represent observed age group specific sero-prevalence points
for the cross sectional survey. The dotted line represents a maximum likelihood fit using these data. The full triangles and unbroken line represent
observed sero-prevalence points and fitted line for the health facility surveys.
doi:10.1371/journal.pone.0006083.g002
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PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e6083Antibody titre was estimated using the formula: titre=dilution/
[maximum OD/(OD test serum- minimum OD)-1]. A cut off
above which samples were deemed antibody positive was defined
using a mixture model as previously described [25]. Briefly, the
distribution of normalized OD values was fitted as the sum of two
Gaussian distributions (a narrow distribution of sero-negatives and
a broader distribution of sero-positives) using maximum likelihood
methods. The mean OD of the Gaussian corresponding to the
sero-negative population plus three standard deviations was used
as the cut-off for sero-positivity (Cook et al, unpublished). A
separate cut off was generated for each antigen (MSP-119 &
AMA-1), each sample type (plasma & filter paper) and each study
(Pilot or IPTi). The sero-conversion rate (SCR or l)w a s
estimated by fitting a simple reversible catalytic model to the
measured sero-prevalence, stratified into yearly age-groups, using
maximum likelihood methods. For these models only individuals
aged 1 and over were included to remove the effect of maternally-
derived antibodies in infants. Additionally, evidence for temporal
changes in SCR was explored by fitting models in which the SCR
is allowed to change at a single time-point. The significance of the
change was identified using likelihood ratio tests against models
with no change, and profile likelihoods were plotted to determine
confidence intervals for the estimated time of the change [30].
Lambda SCR values were converted to EIR equivalents using a
log log regression equation based on previously collected SCR
and EIR values from areas of different transmission intensity in
Tanzania [23,24]. Antigen-specific fixed values of rho, r, the sero-
reversion rate, were fixed based on previous estimates from Tanzania
[24](for MSP-119 rho=0.0173/yr & AMA-1 rho=0.0262/yr). All
analysis was carried out using Stata 10 (Statacorp, Texas US).
Ethical approvals
Ethical approval for the study was obtained from the Tanzanian
National Institute of Medical Research (NIMR/HQ/R.8a/
Vol.IX./553), the Kilimanjaro Christian Medical Centre (KCMC:
#224) and the London School of Hygiene & Tropical Medicine
(LSHTM: #5136).
Results
Pilot study
For the pilot study, samples were collected from 341 individuals
attending the health facility in Msitu wa Tembo over a 4 week
period. Compared with the previous cross-sectional survey, the
proportion of individuals under the age of 1 year was higher than
expected (12.9% vs 4.5%, p,0.001) presumably as a result of
infant attendance at the MCH clinic for routine vaccination
(Table 1). Parasite positivity (as determined by RDT) was also
higher in those recruited at the clinic compared with those
recruited in the cross-sectional surveys (4.7% vs. 2.3%, p,0.001).
Overall, sero-prevalence for MSP-119 was significantly lower at the
health facility than in the cross-sectional survey (29.1% vs. 40.5%,
p=0.005) but antibody sero-prevalence was similar for AMA-1
(46.9% vs. 47.9%, p=0.8). No significant differences in anti-
AMA-1 antibody titres were seen between subjects recruited at the
health facility and and those recruited in the community. Among
children aged under 1 year and children aged 2–5 years, mean
MSP-119 antibody titres were significantly higher among children
recruited at the health facility than among children recruited in
the community. However, in adults, anti-MSP-119 titres were
higher among those recruited in the community than among those
recruited at the health facility (Table 1). In the community surveys,
mean antibody titres were significantly higher in RDT positive
than in RDT negative individuals for both antigens (MSP-119: 216
vs 72 p,0.001; AMA-1: 161 vs 74 P,0.005). Antibody titres were
also higher in RDT positives than RDT negatives in the health
facility survey but not significantly so (MSP-1 titres 63 vs 49
p=0.6; AMA-1 116 vs 65 P=0.08). Age sero-prevalence plots for
each antigen are shown in Figure 2. Estimated SCR values
obtained from the statistical model, assuming no change in
transmission intensity, for health facility and cross-sectional
surveys were not significantly different for AMA-1 [ 0.63 (95%
CI 0.52–0.76) and 0.61 (95% CI 0.56–0.65) respectively; p=0.4]
but the health facility estimate for MSP-119 0.24 (95% CI 0.19–
0.29)] was significantly lower than the cross sectional estimate 0.42
(95% CI0.39–0.45; p=0.012).
Table 2. Distribution of study participants by age group, sex, RDT and sero-positivity to both MSP-119 and AMA-1 for health
facilities in Korogwe and Same districts.
age group total (%) Korogwe Total Same
%
female
% RDT
positive
% MSP-119
seropositive
% AMA-1
seropositive % female
% RDT
positive
% MSP-119
seropositive
% AMA-1
seropositive
,1 348 (17.6) 50.3 4.7 9.9 18.0 240 (12.7) 50.0 0.0 2.1 9.2
1 to 2 90 (4.5) 44.4 21.1 16.9 16.9 94 (4.9) 48.9 1.1 1.1 3.2
2 to 5 161 (8.2) 54.7 24.8 20.0 35.6 135 (7.15) 61.5 0.8 1.5 2.2
5 to 10 143 (7.2) 53.2 32.4 23.1 53.9 122 (6.5) 49.2 2.5 3.4 7.4
10 to 15 94 (4.8) 56.4 17.2 36.2 79.8 126 (6.7) 64.3 0.8 3.3 22.4
15 to 20 127 (6.4) 74.8 11.1 50.0 77.8 182 (9.6) 64.8 4.1 14.4 44.8
20 to 25 172 (8.7) 83.7 7.0 54.1 84.9 160 (8.5) 79.4 0.0 23.1 48.8
25 to 35 371 (18.8) 81.1 4.6 53.4 87.3 290 (15.4) 78.9 0.4 25.6 52.1
35 to 50 273 (13.8) 72.2 2.9 57.4 86.8 283 (15.0) 77.0 1.1 36.9 66.3
.50 195 (9.9) 61.0 2.6 73.2 87.1 256 (13.6) 63.3 0.0 35.6 57.9
Total 1,974 65.3 9.8 40.7 64.1 1,888 65.9 0.9 18.6 37.7
doi:10.1371/journal.pone.0006083.t002
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A total of 3862 subjects were enrolled in the main study with
similar numbers recruited between Korogwe and Same district
sites: subject numbers at individual health facilities ranged from
421 to 499. Two thirds (66.0%) of samples were from those
attending the health facility as patients, the majority of these as
outpatients, and the remainder were accompanying guardians
and/or siblings. Participant age ranged from infancy (4 weeks old)
to 96 years. Although there were no age or gender restrictions on
participation in the study, the age groups showing the greatest
participation were ,4 and .22 years, with an overall mean age of
24 years. Sixty six percent of participants were female, presumably
due to attendance of women at antenatal clinics or as an
accompanying guardian for a child. RDT parasite positivity rate
was higher in the Korogwe health facilities than in Same (Table 2).
ELISA was performed on 3859 filter paper samples for MSP-119
and 3862 samples for AMA-1. Sero-positivity to both antigens
increased with age and was higher in the Korogwe health facilities
(MSP-119 and AMA-1 both p,0.001; Table 2). Antibody
positivity rates were not significantly different between sick
children and children who were well (MSP-119 12.0% vs 8.6%
p=0.1, AMA-1 17.2 vs 19.3 p=0.8). Age sero-prevalence plots for
the Same and Korogwe regions are shown in Figure 3. Visual
assessment of the plots for the Same dispensaries indicated a poor
fit of the model, for younger age groups, where sero-prevalence
was lower than predicted. When a model, which allowed for a
single change in sero-conversion rate was fitted to the combined
data from the 4 Same health facilities, the best fitting model was
that with the change between the two SCRs occurring
approximately 15 years previously (CI 11–18) (i.e.1992) according
to the MSP-119 data (Figure 4a) and 8 years previously (CI 6–14)
(i.e. 1999) according to the AMA-1 data (Figure 4b). We chose a
model compatible with both antigens which assumed that the SCR
in Same changed 10 years previously, which had a significantly
Figure 3. Age sero-prevalence plots for MSP-119 and AMA-1 fitted by maximum likelihood with a single force of infection for the
dispensaries in the Kili-IPTi study. Plot a) MSP-119 Same district; b) AMA-1 Same district; c) MSP-119 Korogwe district and d) AMA-1 Korogwe
district. Black triangles represent observed data and black lines predicted values. Dotted black lines represent upper and lower 95% CI for the
predicted SCR.
doi:10.1371/journal.pone.0006083.g003
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constant (likelihood ratio test for MSP-119 X
2=9.6 p=0.002 and
AMA-1 X
2=45.4 p,0.0001). Sero-prevalence plots for Same
assuming a change in SCR 10 years previously are shown in
Figures 5a and 5b, for MSP-119 and AMA respectively. A change
in SCR was observed for all 4 health facilities in Same (Table 3)
but was not observed for any of those in Korogwe region
(Figures 4c & 4d)(Similar analysis was conducted on pilot survey
data which showed the best fitting model with a single conversion
rate).
The estimated SCR for each health facility, including both the
current estimate and the historical estimates for those in Same, for
each antigen, along with the respective estimates of EIR, are
shown in Table 3. SCRs for the different antigens were correlated
(Pearson correlation coefficient r=0.88, CI 0.78–0.97). Excluding
from the analysis any individuals who were positive for malaria
infection by RDT did not affect the SCR estimate. In Korogwe,
the SCRs calculated using all samples were 0.04 (CI 0.037–0.044)
for MSP-119 and 0.126 (CI 0.115–0.138) for AMA-1 (Table 3).
The corresponding values when RDT positive samples were
excluded from the analysis were 0.037 (0.033–0.041) for MSP-119
and 0.114 (0.103–0.126) for AMA-1. SCRs were not significantly
different when calculated for patients or accompanying individuals
(Table 4). Our estimates of SCR demonstrate that there is
considerable heterogeneity in transmission across the study site
and suggest that the current upper estimates of transmission (i.e.
the upper 95% confidence limit) in the study area range from less
than 0.1 to more than 30 infectious bites per person per year.
Estimated SCR and EIR equivalents show a trend for transmission
to be higher in communities closer to the Indian ocean, as we have
documented previously [27]. In the Same dispensaries our SCR
estimates indicate a 2-fold (Same District Hospital) to ,20-fold
(Kisiwani) decrease in transmission in recent years. Finally, for
each health facility, current SCR values were highly correlated
with clinical malaria incidence rates among infants in the placebo
(untreated) cohort of the contemporaneous IPTi study conducted
at the same sites [26] (Pearson correlation coefficient MSP-119
r=0.78, p,0.01; AMA-1 r=0.91, p,0.001) (Figure 6a & 6b).
Figure 4. Univariate profile likelihood to evaluate the time at which sero-conversion rates changed. Same region fits are represented
in a) for MSP-119 fits and b) for AMA-1. The broken black line is the 95
th percentile of the Chi-squared on 1 degree of freedom below the maximum.
The two points at which this line crosses the log-likelihood profile are used to determine an approximate 95% confidence interval for the time since
the change in SCR i.e. 11–18 years for MSP-119 and 6 to 14 years for AMA-1. The equivalent plots for Korogwe are shown in c) for MSP-119 and d) for
AMA-1.
doi:10.1371/journal.pone.0006083.g004
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In this study we have used the prevalence of antimalarial
antibodies in samples collected from health centre attendees to
generate measures of MTI. Age-specific sero-prevalence rates were
used to estimate sero-conversion rates (SCR), which have
previously been shown to correlate closely with the gold standard
measure of malaria transmission, EIR [23]. Consistent with
previous studies in the same area [27,31], estimated transmission
intensity varied from village to village according to altitude and
proximity to the Indian Ocean and varied more than 10-fold
between geographically adjacent communities (Korogwe EIR
equivalent range between 1 and 14 ib/p/yr). Importantly, the data
point to a recent marked reduction in malaria transmission in one
of the study sites; our best estimate is that EIR in Same region has
fallen by approximately 90% in the last 10 years, in line with
estimates generated from conventional malariometric parameters
from nearby Kenya [5,8,32]. Interpretation of the relationship
between SCR and EIR needs to allow for variation in the
estimates for both measures. Similarly, caution will be required
when comparing these SCR estimates between different areas and
health systems until the degree of bias in an estimate is more fully
understood. However, the measures of MTI generated by this
relatively quick and simple approach could find widespread
application as an operational tool for malaria control programmes.
There are a number of potential limitations associated with
recruitment of individuals for sero-prevalence studies via health
centres. Firstly, attendance for childhood immunisation or
antenatal clinics means that (as seen here) the cohort is likely to
be biased towards recruitment of children under the age of 5 years
and women of child bearing age. Over-representation of small
children and their mothers was observed in the pilot study and
may have contributed to the observed differences in anti-MSP-119
seroprevalence and titres between the health facility and
community surveys. To compensate for this, in the main study,
field workers were encouraged to sample accompanying family
members as well as those seeking health care and this allowed
sufficient numbers of individuals aged from 5 to 20 years to be
recruited at each site to allow estimates of SCR to be obtained
with a sufficient degree of precision. In future studies, numbers in
this age group could also be augmented from surveys in local
schools [33]. Secondly, and perhaps more importantly, many
health centre attendees are ill and, depending on the transmission
intensity, a substantial proportion of these will have active malaria
infections which could, in theory, influence sero-prevalence rates.
In the pilot study there were, predictably, more parasite positive
individuals recruited at the health centres than in the cross
sectional surveys and in both the pilot study and the main study
parasitaemic individuals were 2–3 times more likely to be antibody
positive than aparasitaemic individuals. In the main study,
however, excluding these RDT positive individuals from the
analysis resulted in only marginally lower SCR suggesting that
concurrent patent malaria infections do not bias SCR estimates.
One reason for this may be that sero-prevalence may also be
affected by sub-patent parasite carriage (i.e. parasitaemia that is
below the limit of detection by microscopy and RDT’s). Sub-
patent infections are far more frequent than patent infections, even
at quite low transmission intensities [29,34–36], and it is probable
that similar levels of asymptomatic carriage are present in health
facility attendees and in participants in cross-sectional surveys.
Further work is underway to investigate the impact of patent and
subpatent parasitaemia on SCR. Future studies will also need to
evaluate the impact of HIV infection on malaria seroprevalence.
There are few data relating to the effect of HIV infection on anti-
malarial antibody levels and these data are inconclusive.HIV
infection may reduce anti-malarial antibody concentrations in
pregnant women but has no effect malaria specific antibody
responses in HIV infected neonates [37,38]. Finally, although
most health facilities have defined catchment areas, with the
majority of attendees coming from within this area [39], SCR
estimates for some facilities may be skewed by recruitment of
individuals who come from further away. This is most likely to be
the case for referral facilities and for particularly well-resourced
health facilities on major transit routes. Ideally, such facilities
would not be selected for survey; if this is unavoidable then a
simple question on village of residence could be used to refine the
catchment area or to filter out attendees from outside the local
community.
Whilst a health facility survey has less epidemiological rigour
than a full cluster sampled household based survey, it does have
Figure 5. Age sero-prevalence plots for MSP-119(a) and AMA-1
(b) fitted by maximum likelihood with a two forces of infection
for Same district. Black triangles represent observed data and black
lines predicted values. Dotted black lines represent upper and lower
95% CI for the predicted SCR.
doi:10.1371/journal.pone.0006083.g005
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were available from the 8 sites within 8 weeks of starting the
surveys. The operational requirements were minimal: training and
routine monitoring of health centre staff was performed by 2
project staff travelling between facilities by motorbike and ELISA
assays were all performed by one laboratory technician. This
operational ease is reflected in the cost; a crude comparison of
costs between the health centre surveys (conducted in 2007) and
cross sectional surveys conducted in the same area (in 2001) [27]
suggests a 5- to 10- fold cost saving (US$1–2 per person compared
with US$10–15 per person). These operational benefits are in
addition to the benefits of the increased sensitivity and relative
stability of antibody responses over time compared with using
parasite rate or EIR to determine transmission intensity and the
fact that surveys can be carried out at any time of year rather than
being, restricted to ‘high’ or ‘low’ transmission seasons [24]. With
malaria control activities needing to become increasingly focused
there is a clear case for making more use of routine health facility
data to provide local relevant estimates of transmission [40].
Training and equipment to carry out health facility serological
surveys could be built into the strengthening of the health centre
system, providing important information on the population at risk
from malaria and guiding more detailed surveys to identify high
prevalence communities that may require greater resources from
malaria control programmes and low prevalence communities that
need to be monitored for re-emergence of transmission.
A very important benefit of the sero-prevalence approach to
estimating malaria transmission is the ability to detect historical
changes in MTI. Whilst the step-change in SCR in the four health
facilities in Same district is highly indicative of a marked change in
transmission over the last decade; in theory the same pattern could
be seen if there was an age-related change in risk of malaria
exposure – for example by virtue of travel to or employment in an
area of differing transmission [36]. Whilst, from our knowledge of
the socio-economic and demographic characteristics of this
community, this seems unlikely we need to formally exclude this
possibility. Fortunately, two of the health centres studied here
serve villages for which we have SCR estimates from our previous
village-based cross-sectional surveys in 2001 [23]. In the village of
Kadondo, which is in the catchment of Gonja Maore health
facility in Same district, the AMA-1 SCR from 2001, was 0.112
(CI 0.09–0.13) which is similar to our current estimate of SCR
prior to 1998 (SCR 0.071, CI 0.049–0.103) and noticeably higher
than our current estimate for post-1998 (SCR 0.008, CI 0.003–
0.023). Moreover, there was no evidence of a step-change in SCR
in 10–15 year olds in the data collected in 2001, arguing against
age-related behavioural changes as an explanation for changing
SCR. Taken together with both regional [32] evidence of a
decrease in malaria transmission and a 70% decline in slide
positivity in outpatients to Same hospital between 2002 and 2006
[41], these observations buttress our conclusion of a drop in
transmission intensity in Same District in the mid- to late-1990s.
In Korogwe district, the 2001 SCR value for AMA-1 for Mgila,
which lies within the catchment of Magasin health facility, was
0.187 (CI 0.16–0.22) which compares well with the current
estimate of 0.21 and suggests that malaria transmission may not
have changed here so significantly over the last few years. In
Table 3. Sero-conversion rates and EIR equivalents for MSP-119 and AMA-1 by district and by individual health facility.
Site MSP AMA
Sero conversion
rate CI EIR equivalent CI
Sero conversion
rate CI EIR equivalent CI
Same (all) previous 0.025 0.021–0.03 0.6 0.4–0.9 0.066 0.057–0.078 0.6 0.4–1
Current 0.005 0.002–0.01 0 0–0.1 0.01 0.006–0.016 0 0–0
Same DH previous 0.02 0.015–0.028 0.4 0.2–0.8 0.043 0.031–0.06 0.2 0.1–0.5
Current 0.002 0–0.013 0 0–0.2 0.011 0.004–0.027 0 0–0.04
Kisiwani previous 0.044 0.031–0.062 2 1–4.3 0.133 0.097–0.182 4.7 1.9–11.7
Current 0.003 0–0.022 0 0–0.5 0.005 0.001–0.018 0 0–0.01
Gonja Maore previous 0.023 0.009–0.06 0.5 0.1–4.1 0.071 0.049–0.103 0.8 0.3–2.2
Current 0.008 0.003–0.02 0.06 0–0.4 0.008 0.003–0.023 0 0–0.03
Ndungu previous 0.032 0.024–0.044 1.1 0.6–2.1 0.071 0.049–0.101 0.7 0.26–2.1
Current 0.003 0–0.013 0 0–0.3 0.014 0.007–0.031 0 0.001–0.07
Korogwe (all) 0.04 0.037–0.044 1.7 1.4–2 0.126 0.115–0.138 4 3–5.3
Magunga 0.03 0.025–0.035 0.9 0.6–1.3 0.075 0.064–0.089 0.9 0.5–1.5
Majengo 0.034 0.029–0.041 1.2 0.8–1.7 0.092 0.077–0.11 1.6 0.9–2.7
Mnyuzi 0.063 0.053–0.074 4.4 3.1–6.2 0.188 0.155–0.228 12.8 7.2–22.5
Magasin 0.041 0.034–0.048 1.8 1.2–2.5 0.209 0.171–0.255 17.4 9.8–31.1
doi:10.1371/journal.pone.0006083.t003
Table 4. Sero-conversion rates for MSP-119 and AMA-1 by
district and by individuals attending the health facility as
health seekers or as companions.
Site Antigen Service seekers Companions
Same MSP-1 previous 0.024 (0.018–0.032) 0.028 (0.023–0.034)
current 0.005 (0.002–0.012) 0.000 (0.000–0.000)
AMA-1 previous 0.066 (0.052–0.082) 0.068 (0.053–0.087)
current 0.011 (0.006–0.018) 0.008 (0.003–0.025)
Korogwe MSP-1 0.043 (0.039–0.049) 0.034 (0.030–0.040)
AMA-1 0.134 (0.119–0.152) 0.116 (0.099–0.136)
doi:10.1371/journal.pone.0006083.t004
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MSP-119 estimates for Mgila in 2001 and Magasin in 2008 show a
decrease in SCR from 0.13 (0.9–1.6) to 0.04 (0.03–0.05). Given
the proximity of Same and Korogwe districts, and mounting
regional evidence for change in transmission, it seems likely that
transmission is also gradually declining in Korogwe district. The
differences between the AMA-1 and MSP-119 estimates in
detecting changes in transmission may be linked to differences in
seroconversion and reversion rates and this could also explain the
differences observed in the pilot study. It is likely that
seroconversion and reversion rates are different for different
antigens, possibly reflecting their inherent immunogenicity,
subclass dependent half-life, polymorphism etc. AMA-1 appears
to be more immunogenic than MSP-119, and anti-AMA-1 titers
tend to be higher than those for MSP-119, suggesting that
seroconversion may be faster and sero-reversion may be slower for
AMA-1 than for MSP-119. However, the extent to which these
differences influences estimates of malaria transmission is not yet
clear and is the subject of ongoing analysis in our group.
The reasons for the decline in MTI are unclear. The Same area
was once hyperendemic for malaria and was part of the Pare-
Taveta malaria control scheme of the 1950s [42]; although this
scheme was short-lived it was highly effective and, transmission
was still lower 20 years on [43]. In recent years we have found no
evidence of concerted, systematic interventions in the area. Bed
net use was 40% in 2001 with 10% of these insecticide treated
[27]. Whilst ITN use has undoubtedly increased since then [44] it
is unlikely to explain this major drop in transmission. Sociological
Figure 6. Current sero-conversion rates and clinical malaria incidence rates in the IPTi placebo cohort for each health facility: (a) for
MSP-119 and (b) for AMA-1. Vertical bars indicate the 95% CI for SCR and horizontal bars indicate the 95% CI for malaria incidence. Fitted lines
represent linear regression plots. R
2 values for MSP-119 and AMA are 0.78 and 0.91, respectively.
doi:10.1371/journal.pone.0006083.g006
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health interventions and better housing, as well as meteorological
parameters (e.g. mean annual rainfall has dropped from 600 mm
pa to 500 mm pa in the last 15 years) are all likely to have an effect
on transmission.
In summary, we have used a rapid, health centre-based,
serological survey to provide local estimates of malaria transmis-
sion intensity. These estimates are consistent with cross-sectional
data collected previously in the same communities, emphasise the
heterogeneity in transmission within a relatively restricted
geographical area and have allowed quantification of the recent
drop in malaria transmission in the region. The envisaged value of
this serological approach [11,12,45] is being born out and the fact
that these data can be generated quickly, cheaply and easily
through the existing health infrastructure represents a potentially
important innovation for implementation and monitoring malaria
control activities.
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